Tolero Pharma

Lehi, United States Founded: 2011 • Age: 15 yrs Acquired By Sumitomo Dainippon Pharma
Therapeutics for cancer and blood disorders are developed.

About Tolero Pharma

Tolero Pharma is a Healthcare company based in Lehi (United States) founded in 2011, and was acquired by Sumitomo Dainippon Pharma in December 2016. Therapeutics for cancer and blood disorders are developed. Tolero Pharma has raised $48.23 million across 4 funding rounds from investors including Alger and Sumitomo Dainippon Pharma. The company has 17 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.

Company details

Tolero Pharma was founded in 2011 and is based in Lehi, United States. Operations focus on the development of therapeutics targeting biological drivers of blood disorders, including leukemias and anemia. The pipeline features an immunotherapeutic cancer vaccine as the lead candidate, along with inhibitors for AXL, CDK9, ALK2, PIM, and BTK. Efforts center on oncology within the biopharmaceutical sector.

Operational Areas
Key Metrics
  • Total Equity Funding
    $48.23M (USD)

    in 4 rounds

  • Latest Funding Round
    $8.2M (USD), Series B

    Dec 2014

  • Investors
    Alger

    & 1 more

  • Employee Count
    17
  • Acquired by

Funding Insights of Tolero Pharma

Tolero Pharma has successfully raised a total of $48.23M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $8.2 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $48.23M
  • Total Rounds 4
  • Last Round Series B β€” $8.2M
  • First Round $3.33M

    (Jul 2012)

  • Investors Count 1

All 4 funding rounds of Tolero Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2014$8.2MSeries B–Alger
–
Nov 2014$22.5MSeries B––
Aug 2014$14.2MSeries B–Alger
–
Jul 2012$3.33MSeries A––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Tolero Pharma

Tolero Pharma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Alger and Sumitomo Dainippon Pharma.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
ESG investments are managed by this venture capital firm.
1964alger.comNew York, United States
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured.
1897ds-pharma.comOsaka, Japan
Premium access

Investor details for Tolero Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Tolero Pharma

4 dated milestones of Tolero Pharma across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Tolero Pharma is founded.
  2. Funding First funding round of $3.3M.
  3. Funding Latest funding round, Series B, of $8.2M.
  4. Exit Acquired by Sumitomo Dainippon Pharma.

Competitors of Tolero Pharma

Tolero Pharma has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
incyte.com1991Wilmington, United States1,387
Small molecules are developed for cancer and skin disease treatments.
Premium access

Detailed competitors of Tolero Pharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as Tolero Pharma (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Tolero Pharma

Premium access

Complete news archive for Tolero Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tolero Pharma

Tolero Pharma was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Tolero Pharma is headquartered in Lehi, United States. It is registered at Lehi, Utah, United States.

Tolero Pharma is a funded company, having raised a total of $48.23M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.33M, raised on Jul 2012.

Tolero Pharma has 17 employees.

Tolero Pharma was founded in 2011 and is based in Lehi, United States. Operations focus on the development of therapeutics targeting biological drivers of blood disorders, including leukemias and anemia. The pipeline features an immunotherapeutic cancer vaccine as the lead candidate, along with inhibitors for AXL, CDK9, ALK2, PIM, and BTK. Efforts center on oncology within the biopharmaceutical sector.

Tolero Pharma's top competitors include Moderna, BeiGene and Incyte.

Tolero Pharma has 2 investors. Key investors include Alger, and Sumitomo Dainippon Pharma.

Yes. Tolero Pharma was acquired by Sumitomo Dainippon Pharma in December 2016.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available